Hammond, Flora M.
Katta-Charles, Sheryl
Russell, Mary Beth
Zafonte, Ross D.
Claassen, Jan
Wagner, Amy K.
Puybasset, Louis
Egawa, Satoshi
Laureys, Steven
Diringer, Michael
Stevens, Robert D.
,
Article History
Received: 26 February 2021
Accepted: 22 May 2021
First Online: 8 July 2021
Declarations
:
: The authors do not possess any relevant conflicts of interest to disclose. Dr. Hammond reports grants from NIDILRR, personal fees from Avanir, personal fees from Lash Publishing, Inc, personal fees from Demos Publishing, outside the submitted work. Drs. Katta-Charles, Wagner, Egawa, Laureys, and Diringer have nothing to disclose. Dr. Russell reports personal fees from Merz, personal fees from Allergan, outside the submitted work. Dr. Zafonte reports past royalties from (1) Oakstone for an educational CD- Physical Medicine and Rehabilitation a Comprehensive Review; (2) Springer/Demos publishing for serving as co- editor of the text Brain Injury Medicine. Dr Zafonte serves on or previously served on the Scientific Advisory Board of Myomo, Oxeia Biopharma, ElMINDA and Biodirection. Dr. Claassen reports grants from NINDS R01 NS106014 , grants from McDonnell Foundation, grants from NINDS R03 NS112760, other from iCE Neurosystems, outside the submitted work. Dr. Puybasset reports grants from EU- CenterTBI, grants from French ANR, during the conduct of the study; personal fees from BRAINTALE, outside the submitted work; In addition, Dr. Puybasset has a patent WO2012160316 issued. Dr. Stevens reports other from Edwards Lifesciences outside the submitted work.
: The Curing Coma Campaign is supported by the Neurocritical Care Society.